GLUCAGON-LIKE peptide 1 receptor agonists (GLP-1RAs), including semaglutide (Ozempic, Wegovy), liraglutide, and tirzepatide, could be linked to an increased risk of neovascular age-related macular degeneration (nAMD) in patients with diabetes, researchers have found.
A study involving almost 140,000 people found that more than twice as many patients with diabetes who took GLP1-RAs developed nAMD compared to similar patients who had not, and the risk was highest (more than three times as high) among those with the longest exposure.
While the overall risk was still low, the authors recommended clinicians should keep an eye out for potential complications, and consider the trade-off between risks and benefits.
The above article was sent to subscribers in Pharmacy Daily's issue from 10 Jun 25
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 10 Jun 25
